Giant Biogene

Giant Biogene is a China-listed leader in recombinant collagen and professional skin care, known as the "first collagen stock" after its November 2022 IPO on the Hong Kong Stock Exchange (02367.HK) . The company was founded around research by Fan Daidi, a leading figure in China's biomedical materials field, and built a synthetic biology platform spanning biotechnology, biochemistry, and bioengineering . By the time of listing it had developed 33 types of recombinant collagen for mass production, alongside rare ginsenosides, and its flagship brands Kefumei (可复美) and Kelijin (可丽金) ranked third and fourth in China's professional skin care market by 2021 retail sales . Gaorong Ventures participated in its only pre-IPO financing round in October 2021 . More recently, as of August 2024, Giant Biogene received a national invention patent for recombinant human type XVII collagen, extending its portfolio into hair follicle repair and scalp care applications .